Search

Your search keyword '"Pihla Pakkanen"' showing total 2 results
Start Over Author "Pihla Pakkanen" Publication Year Range Last 10 years
2 results on '"Pihla Pakkanen"'

1. Survival and Larynx Preservation in Early Glottic Cancer: A Randomized Trial Comparing Laser Surgery and Radiation Therapy

Author

Pihla Pakkanen, Heikki Irjala, Taru Ilmarinen, Elina Halme, Paula Lindholm, Antti Mäkitie, Tuija Wigren, Leena-Maija Aaltonen, Korva-, nenä- ja kurkkutautien klinikka, HUS Head and Neck Center, Faculty Common Matters (Faculty of Medicine), Clinicum, and Research Program in Systems Oncology

Subjects
Male, Glottis, Cancer Research, CARCINOMA, 3122 Cancers, VOICE QUALITY, QUALITY-OF-LIFE, Humans, Radiology, Nuclear Medicine and imaging, Prospective Studies, Laryngeal Neoplasms, METAANALYSIS, Neoplasm Staging, Retrospective Studies, Radiation, Squamous Cell Carcinoma of Head and Neck, CO2-LASER SURGERY, 3126 Surgery, anesthesiology, intensive care, radiology, Tongue Neoplasms, Survival Rate, Treatment Outcome, Oncology, Head and Neck Neoplasms, Female, Laser Therapy, RADIOTHERAPY
Abstract

Purpose: The prognosis of glottic T1a laryngeal squamous cell carcinoma (LSCC) is excellent with both transoral laser surgery (TLS) and radiation therapy (RT). Our aim was to compare TLS and RT treatment results in a randomized study. Methods and Materials: Of 56 male patients with glottic T1a LSCC, 31 were randomized for TLS and 25 for RT. Survival and larynx preservation data were collected from medical records. Results: Five-year overall survival (OS) was 87%, disease-specific survival (DSS) was 97%, and recurrence-free survival (RFS) was 81% in patients treated with TLS. Five-year OS was 92%, DSS was 100%, and RFS was 88% in patients treated with RT. The primary treatment method was not associated with OS, RFS, or DSS in a log-rank test. The larynx preservation rate was similar in both groups (TLS, 97%; RT, 92%; P = .575). Conclusions: In a prospective randomized setting oncological outcomes of both treatment modalities (TLS or RT) for T1a LSCC were similar. (C) 2022 Elsevier Inc. All rights reserved.

Published
2022
Full Text
View/download PDF

2. Pancreatic Secretory Trypsin Inhibitor (SPINK1) Gene Mutation in Patients with Acute Alcohol Pancreatitis (AAP) Compared to Healthy Controls and Heavy Alcohol Users without Pancreatitis

Author

Anssi Nikkola, Kari Mäkelä, Karl-Heinz Herzig, Shivaprakash Mutt, Aishwarya Prasannan, Hanna Seppänen, Terho Lehtimäki, Mika Kähönen, Olli Raitakari, Ilkka Seppälä, Pihla Pakkanen, Isto Nordback, Juhani Sand, Johanna Laukkarinen, Tampere University, Department of Gastroenterology, Clinical Medicine, Department of Clinical Chemistry, Department of Clinical Physiology and Nuclear Medicine, and Department of General Administration

Subjects
Ethanol, Organic Chemistry, serine protease inhibitor Kazal-type 1, acute alcohol pancreatitis, alcoholics, General Medicine, 3121 Internal medicine, 3142 Public health care science, environmental and occupational health, Catalysis, Computer Science Applications, Inorganic Chemistry, SPINK1, Pancreatitis, Trypsin Inhibitor, Kazal Pancreatic, Risk Factors, Mutation, Humans, Genetic Predisposition to Disease, Trypsin, genetics, Physical and Theoretical Chemistry, genes, Molecular Biology, Spectroscopy
Abstract

Only 3–5% of heavy alcohol users develop acute alcohol pancreatitis (AAP). This suggests that additional triggers are required to initiate the inflammatory process. Genetic susceptibility contributes to the development of AAP, and SPINK1 mutation is a documented risk factor. We investigated the prevalence of the SPINK1(N34S) mutation in patients with AAP compared to heavy alcohol users who had never suffered an episode of pancreatitis. Blood samples for the mutational analysis from patients with first episode (n = 60) and recurrent AAP (n = 43) and from heavy alcohol users without a history of AAP (n = 98) as well as from a control population (n = 1914) were obtained. SPINK1 mutation was found in 8.7% of the patients with AAP. The prevalence was significantly lower in healthy controls (3.4%, OR 2.72; 1.32–5.64) and very low in alcoholics without pancreatitis (1.0%, OR 9.29; 1.15–74.74). In a comparison adjusted for potential cofounders between AAP patients and alcoholics, SPINK1 was found to be an independent marker for AAP. The prevalence of the SPINK1 mutation is overrepresented in AAP patients and very low in alcoholics without pancreatitis. This finding may play a role in understanding the variable susceptibility to AAP found in heavy alcohol users. publishedVersion

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results